Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial.
about
Validity of the decreased sexual desire screener for diagnosing hypoactive sexual desire disorder.First Pharmacological Therapy for Hypoactive Sexual Desire Disorder in Premenopausal Women: Flibanserin.Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder.Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health.Flibanserin: Approval of a controversial drug for a controversial disorderA biopsychosocial approach to women's sexual function and dysfunction at midlife: A narrative review.Commentary on "Critical flaws in the FSFI and IIEF".Flibanserin: First Global Approval.Skills Vs. Pills: Comparative Effectiveness for Low Sexual Desire in Women.New developments in the treatment of hypoactive sexual desire disorder - a focus on Flibanserin.A Practical Approach to Managing Hypoactive Sexual Desire Disorder in Women with Diabetes.Female sexual dysfunction: a focus on flibanserin.Effect of Flibanserin Treatment on Body Weight in Premenopausal and Postmenopausal Women with Hypoactive Sexual Desire Disorder: A Post Hoc Analysis.Flibanserin-Stimulated Partner Grooming Reflects Brain Metabolism Changes in Female Marmosets.Disentangling desire and arousal: a classificatory conundrum.Response to Rosen et al. ( 2014 ) "Commentary on 'Critical flaws in the FSFI and IIEF'".Flibanserin.Evaluation and Management of Hypoactive Sexual Desire Disorder.Female Sexual Function at Midlife and Beyond
P2860
Q30456335-78111DA6-76FB-4437-9428-393C24234003Q33166596-74717D09-67C5-4557-AEB6-3A9FE78ED678Q34043125-AA344BB6-87AB-4FAA-ADAA-8D47C066928FQ34336933-07360F6B-C842-44C4-8E2A-2409C1D4F704Q36216746-A59233E6-7EA9-4C5A-A9D0-93E02A40CB84Q36730209-829CA1A5-B65C-4B66-9404-C5C846B93104Q38211669-5FB55B22-1CEC-4160-ABE1-46D0AF39DDB9Q38594117-5B36F69D-3FE6-4EB3-83B6-CB979A35BB6AQ38746601-D79C794A-1B27-4112-8217-CC65141F1625Q39262633-ECD5A2C0-636F-46BB-9A87-E3B78D454201Q42371760-DB694767-DC09-4ABB-BAEB-C6138EEEB632Q42688204-2030C9F5-9ADB-4A0A-9276-A5331FC2A812Q45065520-05685BDE-9F97-462D-95D1-8D51507D0B4AQ48094293-31EB2078-E102-4F84-95EB-C81650326A8DQ50715974-9CACAC5C-7DD0-4606-BBA4-89AE8C63F7FBQ51140278-77208C96-65C5-41F9-A4F6-C8E59931A392Q52149146-8BA8C920-037A-457E-A34A-908E4628A28AQ53437731-40F814A8-E36C-4F9A-B040-1794CED75168Q58551787-9666BA00-A283-4D13-983F-AD08583DF745
P2860
Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Continued efficacy and safety ...... a randomized withdrawal trial.
@en
Continued efficacy and safety ...... oactive Sexual Desire Disorder
@nl
type
label
Continued efficacy and safety ...... a randomized withdrawal trial.
@en
Continued efficacy and safety ...... oactive Sexual Desire Disorder
@nl
prefLabel
Continued efficacy and safety ...... a randomized withdrawal trial.
@en
Continued efficacy and safety ...... oactive Sexual Desire Disorder
@nl
P2093
P1476
Continued efficacy and safety ...... a randomized withdrawal trial.
@en
P2093
Evan R Goldfischer
Jeffery Breaux
Joel Kaufman
Michael Sand
Molly Katz
Toshio Kimura
William B Smith
P304
P356
10.1111/J.1743-6109.2011.02458.X
P577
2011-09-20T00:00:00Z